S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

Why Ascendis Pharma Shares Hit an All-Time High

Photo of Chris Lange
By Chris Lange Updated Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Why Ascendis Pharma Shares Hit an All-Time High

© svetikd / Getty Images

Ascendis Pharma A/S (NASDAQ: ASND) was another biotech firm that saw its shares rise sharply on Monday (after a buyout announcement). In this case, Ascendis shares were up as the result of positive top-line results from its late-stage growth hormone study in children.

Specifically, results came from the Ascendis phase 3 heiGHt Trial that compared once-weekly TransCon Growth Hormone (hGH) to a daily growth hormone (Genotropin) in children with pediatric growth hormone deficiency.

Ultimately, the trial met its primary objective demonstrating that TransCon hGH was observed to be non-inferior and, additionally, superior to the daily hGH on the primary endpoint of annualized height velocity (AHV) at 52 weeks.

In the primary analysis of the intent-to-treat population, TransCon hGH demonstrated an AHV of 11.2 cm per year compared to 10.3 cm per year for the daily hGH. The treatment difference was 0.86 cm per year with a 95% confidence interval of 0.22 to 1.50 cm per year. The AHV for TransCon hGH was significantly greater than the daily hGH.

[nativounit]

Results from the trial indicate that TransCon hGH generally was safe and well-tolerated, with adverse events consistent with the type and frequency observed with daily hGH therapy and comparable between arms of the trial.

Jan Mikkelsen, Ascendis Pharma’s president and CEO, commented:

The heiGHt Trial results announced today represent a potential breakthrough for patients and future treatment options for growth hormone deficiency. The heiGHt Trial demonstrated that TransCon hGH had superior efficacy, as well as comparable safety and tolerability to daily growth hormone. We believe these results provide a validation of our TransCon technology platform, which forms the basis of our endocrinology pipeline and has potential application in other therapeutic areas.

Shares of Ascendis were last seen up about 67% at $115.73, in a new 52-week range of $53.21 to $116.00. The consensus price target is $85.78.

[recirclink id=531809]

[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Continue Reading

Is This the Death of Versartis?
Chris Lange |

Is This the Death of Versartis?

Versartis shares absolutely cratered on Friday after the firm announced results from its late-stage Velocity clinical trial of somavaratan in…
Chris Lange |

Intra-Cellular Shares Continue to Climb on Positive Results

Intra-Cellular Therapies announced positive results from the first Phase 3 clinical trial of ITI-007 for the treatment of patients with…
Is BioCryst Reaching Crush Depth?
Jon C. Ogg |

Is BioCryst Reaching Crush Depth?

BioCryst Pharmaceuticals shares were crushed after it announced results from OPuS-2 for the treatment of hereditary angioedema attacks.
Why This Epilepsy Study Is Huge for Marinus Pharmaceuticals
Chris Lange |

Why This Epilepsy Study Is Huge for Marinus Pharmaceuticals

The announcement of positive topline results in a late-stage epilepsy trial prompted a rally in Marinus Pharmaceuticals shares on Tuesday.
Chris Lange |

Xenoport Rises on Solid Phase 2 Results

Xenoport made waves in Tuesday morning’s premarket trading session on news of positive clinical trial results.
Catabasis Wins With Early-Stage Duchenne Muscular Dystrophy Study
Chris Lange |

Catabasis Wins With Early-Stage Duchenne Muscular Dystrophy Study

Catabasis Pharmaceuticals shares made a handy gain on Tuesday after the company announced early stage data from its Duchenne muscular…
Why Minerva’s Incredible Move May Be Justified
Chris Lange |

Why Minerva’s Incredible Move May Be Justified

Minerva Neurosciences saw its shares make absolutely massive gains on Thursday following the release of positive results from a couple…
Why MyoKardia’s Late-Stage Hypertophric Cardiomyopathy Study Is a Big Hit
Chris Lange |

Why MyoKardia’s Late-Stage Hypertophric Cardiomyopathy Study Is a Big Hit

MyoKardia shares made an incredible gain on Monday after the company announced positive results from its late-stage pivotal clinical trial…
Why RedHill Is Monday’s Big Biopharma Winner
Chris Lange |

Why RedHill Is Monday’s Big Biopharma Winner

RedHill Biopharma shares made a solid gain early on Monday after the firm announced positive results from its late-stage trial…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618